Ocular Therapeutix (OCUL) Projected to Post Quarterly Earnings on Tuesday

Ocular Therapeutix (NASDAQ:OCUL) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Ocular Therapeutix to post earnings of ($0.28) per share and revenue of $17.02 million for the quarter.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Stock Up 5.4 %

Shares of OCUL opened at $8.13 on Tuesday. The company has a 50-day simple moving average of $7.27 and a 200-day simple moving average of $8.45. The firm has a market capitalization of $1.29 billion, a P/E ratio of -6.16 and a beta of 1.49. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix has a 52 week low of $4.62 and a 52 week high of $11.78.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on OCUL. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target for the company. William Blair began coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an “outperform” rating for the company. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. Finally, JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.38.

Insider Transactions at Ocular Therapeutix

In other news, insider Donald Notman sold 6,301 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the sale, the insider now owns 204,563 shares of the company’s stock, valued at approximately $1,603,773.92. This trade represents a 2.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,895 shares of company stock valued at $283,772. Corporate insiders own 3.50% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.